Danaher Stock News

These seven companies are transforming steady profits into rising passive income streams for investors.

Danaher reported okay Q3 earnings, with "cautiousness" probably being the best adjective to describe the release. The company has finally returned to growth and forward-looking commentary seems positive, but management seems reluctant to put numbers around their optimism. There might be a reason behind the conservativeness, which I explain in this article.

Danaher Corporation (NYSE:DHR ) Q3 2024 Earnings Call Transcript October 22, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer Blair - President and CEO Matt McGrew - EVP and CFO Conference Call Participants Tycho Peterson - Jefferies Michael Ryskin - Bank of America Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Scott Davis - Melius Research Puneet Souda - Leerink ...

Danaher on Tuesday beat Wall Street estimates for third-quarter profit on strong demand for its diagnostics and bioprocessing businesses, alongside growth in its molecular testing unit.

WASHINGTON , Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024.  All results in this release reflect only continuing operations unless otherwise noted.

Eine überraschend gute Geschäftsentwicklung des US-Wettbewerbers Danaher US2358511028 hat am Dienstag auch die Aktien von Sartorius DE0007165631 angetrieben.

Learning from successful hedge funds like Millennium means focusing on minimizing risks. To achieve this, I focus on companies with strong pricing power. They have wide moats and recurring revenue that help protect against economic downturns. I've identified three dividend stocks that stand out for their pricing power, market leadership, and ability to generate sustainable long-term returns.

I reiterate my 'Strong Buy' rating for Danaher, with a one-year price target of $310 per share, citing recovery in bioprocessing and market share gains in molecular testing. Danaher's bioprocessing market shows high-single-digit growth in orders, with stabilization in China, and is expected to sustain recovery in Q3 and FY25. Cepheid's market share gains in molecular testing, including FDA auth...